SY
Symbiotec Pharmalab Ltd (SYMBIOTEC)
₹1,143.50
Mkt cap
₹7,037 Cr
P/E ratio
61.00
P/B
—
Div yield
0.00%
ROE
11.70%
ROCE
13.00%
EPS (TTM)
₹18.75
Book value
—
52W range
934–1,246
Sector
Healthcare
Price history
Previous close
Symbiotec is a research-driven, science- based pharmaceutical and biotechnology company with a strong global leadership position in Corticosteroid and Steroidal Hormone Active Pharmaceutical Ingredients (APIs). It has evolved from a Lab-Scale Steroid manufacturer into a fully integrated global platform. [1]
NSE SYMBIOTECBSE 544889
Health check
Cautious
ValuationExpensive
ProfitabilityAverage
GrowthModerate
TechnicalsNeutral
52-week range
−8.23% from high₹1,144
₹934+22.40% from low₹1,246
Current
₹1,143.50
Prev close
₹1,166.00
Day
−1.93%
Price performance
1D
−1.93%
1W
+8.31%
1M
+6.19%
3M
—
6M
—
1Y
—
YTD
+4.17%
Financials
Revenue, profit & margin
P/E ratio
61.0×
SYMBIOTEC is 77% above the sector median of 34.6×
SYMBIOTEC61.0×
Sector median34.6×
| Jun 2025 | Jun 2026NSE | Trend | |
|---|---|---|---|
| Sales | 203 | 218 | |
| Expenses | 145 | 173 | |
| Operating Profit | 58 | 45 | |
| OPM % | 29% | 21% | |
| Other Income | 3 | 0 | |
| Interest | 5 | 6 | |
| Depreciation | 11 | 22 | |
| Profit before tax | 45 | 18 | |
| Tax % | 33% | 20% | |
| Net Profit | 30 | 14 | |
| EPS in Rs | 46.99 | 2.24 | |
| Raw PDF | — |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move −3.04% · closed higher next day 0 of last 1
| Q1FY27 | |
|---|---|
| Broadcast | 21 Sept '26◦ |
| Earnings day | −3.04% |
| +1 day | −8.14% |
| +5 days | −1.03% |
| +15 days | — |
| +30 days | — |
| Filing | XBRL |
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
as of Sep 202633.28%Promoter
Promoters33.28%
FIIs21.08%
DIIs27.51%
Public18.12%
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,837.30 | 34.90 | 4,40,830 | 0.87% | 2,901 | +5.95% | 15,300 | +10.46% | 20.53% |
| Divi's Lab. | ₹9,375.00 | 83.54 | 2,48,877 | 0.32% | 902 | +65.50% | 3,080 | +27.80% | 21.97% |
| Torrent Pharma. | ₹4,840.00 | 82.51 | 1,84,098 | 0.79% | 566 | +5.79% | 4,921 | +54.85% | 15.19% |
| Zydus Lifesci. | ₹1,160.00 | 23.77 | 1,15,710 | 0.09% | 990 | −35.09% | 8,017 | +21.96% | 21.14% |
| Cipla | ₹1,394.50 | 31.48 | 1,12,656 | 0.93% | 786 | −39.19% | 7,119 | +2.33% | 15.49% |
| Laurus Labs | ₹1,954.00 | 96.56 | 1,05,577 | 0.10% | 362 | +125.49% | 2,026 | +29.10% | 17.76% |
| Aurobindo Pharma | ₹1,734.00 | 26.39 | 99,771 | 0.23% | 1,032 | +28.11% | 9,150 | +16.30% | 12.86% |
| Symbiotec Pharma | ₹1,095.10 | 61.02 | 7,037 | 0.00% | 30 | — | 203 | — | 12.99% |
| Median: 158 Co. | ₹433.90 | 34.56 | 2,205 | 0.08% | 13 | +29.57% | 164 | +18.57% | 14.96% |
Filings
Annual reports1
Credit ratings1
Announcements5
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 17 Sep - Dear Sir / Madam, Pursuant to above referred Listing Regulations, we enclose herewith the details of the 'Earnings Conference Call / Analysts Meet' to discuss …Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011. 12 Sep - Promoters disclosed re-creation of pledge over shares on September 11, 2026 after IPO lock-in.Board Meeting Intimation for Prior Intimation Of The Meeting Of The Board Of Symbiotec Pharmalab Limited ('The Company') To Be Held On September 21, 2026 11 Sep - Board meets on 21 Sep 2026 to approve Q1 FY27 standalone and consolidated results.Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011 11 SepUpdate On Intimation Under Regulation 8(2) Of The SEBI (Prohibition Of Insider Trading) Regulations, 2015. 3 Sep - Symbiotec disclosed its Fair Disclosure Code under SEBI PIT Regulations.